Scholarlink

<p>The phosphodiesterase 4B (PDE4B) subtype, a member of the phosphodiesterase (PDE) family, plays a key role in promoting anti-inflammatory and antifibrotic effects by controlling the rate of cyclic adenosine phosphate degradation. To date, inhibitors targeting PDE4B have been widely used in the development of therapeutic agents for pulmonary fibrosis, inflammation, cancer, Alzheimer's disease, adipose tissue dysfunction and chronic liver injury. With the development of techniques such as molecular docking studies, more and more PDE4B inhibitors with different core scaffolds have been discovered, and at least six of these molecular structures have been approved for marketing or entered clinical studies. In this work, we reviewed the PDE4B inhibitors reported in the literature since 2014 and classified the most representative examples with different biological activities according to their structural characteristics. We also made a preliminary analysis of their structure–activity relationship based on the classification results and the conclusions reported in the relevant literature. In addition, we describe the inhibition selectivity of some compounds to PDE4B and PDE4D enzymes, as inhibition of PDE4D is often associated with side effects such as nausea and emesis. We hope that this work will help researchers in the design and optimization of novel PDE4B selective inhibitors and provide a reference for readers who are new to this field.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Phosphodiesterase 4B (PDE4B) inhibitors and their applications in recent years (2014 to early 2025)

  • 期刊论文

  • 发表日期：

    2025年6月14日

查看全文
  • Jing Zhang,
  • Jiadai Zhai,
  • Hui Liu,
  • Hongying Liu,
  • Bingxia Sun,
  • Jie Gao,
  • Feng Sang

摘要

The phosphodiesterase 4B (PDE4B) subtype, a member of the phosphodiesterase (PDE) family, plays a key role in promoting anti-inflammatory and antifibrotic effects by controlling the rate of cyclic adenosine phosphate degradation. To date, inhibitors targeting PDE4B have been widely used in the development of therapeutic agents for pulmonary fibrosis, inflammation, cancer, Alzheimer's disease, adipose tissue dysfunction and chronic liver injury. With the development of techniques such as molecular docking studies, more and more PDE4B inhibitors with different core scaffolds have been discovered, and at least six of these molecular structures have been approved for marketing or entered clinical studies. In this work, we reviewed the PDE4B inhibitors reported in the literature since 2014 and classified the most representative examples with different biological activities according to their structural characteristics. We also made a preliminary analysis of their structure–activity relationship based on the classification results and the conclusions reported in the relevant literature. In addition, we describe the inhibition selectivity of some compounds to PDE4B and PDE4D enzymes, as inhibition of PDE4D is often associated with side effects such as nausea and emesis. We hope that this work will help researchers in the design and optimization of novel PDE4B selective inhibitors and provide a reference for readers who are new to this field.